Cantharidin as an antitumor agent: A retrospective review

Current Medicinal Chemistry

Volumn 20, Issue 2, 2013, Pages 159-166

  Deng, L P ^a,b   Dong, J ^a   Cai, H ^a,c   Wang, W ^d  

^a SHAOXING UNIVERSITY   (China)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c NINGBO UNIVERSITY   (China)

^d Zhejiang Supor Pharmaceuticals   (China)

Author keywords

Antitumor; Cantharidin; Norcantharidin; Structure Activity Relationship

Indexed keywords

ANTINEOPLASTIC AGENT; CANTHARIDIN; CARBOPLATIN; CISPLATIN; CYCLOOXYGENASE 2; DEMETHYLCANTHARIDIN; DIMETHYL SULFOXIDE; DOXORUBICIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; NORCANTHARIDIN; NORCANTHARIMIDE; OXALIPLATIN; PHOSPHOPROTEIN PHOSPHATASE; PHOSPHOPROTEIN PHOSPHATASE 1; PHOSPHOPROTEIN PHOSPHATASE 2A; PHOSPHOPROTEIN PHOSPHATASE INHIBITOR; PLATINUM COMPLEX; PROSTAGLANDIN E2; PROTEIN BAX; PROTEIN BCL 2; STEROID; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLADDER CANCER; CANCER PATIENT; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PHASE; CELL CYCLE REGULATION; CELL PROLIFERATION; COLORECTAL CANCER; CYTOTOXICITY; DNA REPAIR; DRUG MECHANISM; DRUG SYNTHESIS; HEPATOMA CELL; HUMAN; IC 50; LEUKEMIA; LIVER CELL CARCINOMA; OXIDATIVE STRESS; PANCREAS CANCER; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; RETROSPECTIVE STUDY; REVIEW; STRUCTURE ACTIVITY RELATION; TREATMENT INDICATION; TUMOR CELL LINE;

EID: 84877959384     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986713804806711     Document Type: Review

References (98)

1. Oaks, W. W.; DiTunno, J. F.; Magnani, T.; Levy, H. A.; Mills, L. C. Cantharidin poisoning. Arch. Intern. Med., 1960, 105, 574-582.
2. Wang, G. S. Medical uses of mylabris in ancient China and recent studies. J. Ethnopharmacol., 1989, 26, 147-162.
3. Epstein, W. L.; Kligman, A. M. Treatment of warts with cantharidin. Arch. Dermatol., 1958, 77, 508-511.
4. Moed, L.; Shwayder, T. A.; Chang, M. W. Cantharidin revisited: a blistering defense of an ancient medicine. Arch. Dermatol., 2002, 137, 1357-1360. (Pubitemid 32954188)
5. Eldridge, R.; Casida, J. E. Cantharidin effects on protein phosphatases and the phosphorylation state of phosphoproteins in mice. Toxicol. Appl. Pharmacol., 1995, 130, 95-100.
6. Honkanen, R. E. Cantharidin, another natural toxin that inhibits the activity of serine/threonine protein phosphatases types 1 and 2A. FEBS Lett., 1993, 330, 283-286. (Pubitemid 23276340)
7. Li, Y. M.; Casida, J. E. Cantharidin-binding protein: identification as protein phosphatase 2A. Proc. Natl. Acad. Sci. U.S.A., 1992, 89, 11867-11870. (Pubitemid 23004745)
8. McCluskey, A.; Ackland, S. P.; Gardiner, E.; Walkom, C. C.; Sakoff, J. A. The inhibition of protein phosphatases 1 and 2A: a new target for rational anti-cancer drug design? Anticancer Drug Design, 2001, 16, 291-303.
9. To, K. K.; Wang, X.; Yu, C. W.; Ho, Y. P.; Au-Yeung, S. C. Protein phosphatase 2A inhibition and circumvention of cisplatin cross-resistance by novel TCM-platinum anticancer agents containing demethylcantharidin. Bioorg. Med. Chem., 2004, 12, 4565-4573. (Pubitemid 39044348)
10. Shan, H. B.; Cai, Y. C.; Liu, Y.; Zeng, W. N.; Chen, H. X.; Fan, B. T.; Liu, X. H.; Xu, Z. L.; Wang, B.; Xian, L. J. Cytotoxicity of cantharidin analogs targeting protein phosphatase 2A. Anti-Cancer Drugs, 2006, 17, 905-911. (Pubitemid 44350609)
11. Rauh, R.; Kahl, S.; Boechzelt, H.; Bauer, R.; Kaina, B.; Efferth, T. Molecular biology of cantharidin in cancer cells. Chin. Med., 2007, 2-8.
12. Fillmore, K.; Bagatell, K.; Dugan, B. S. Phospholipids and cantharidin induced acantholysis in human epidermis. J. Invest. Dermatol., 1966, 47, 606-611.
13. Peng, F.; Wei, Y. Q.; Tian, L.; Yang, L.; Zhao, X.; Lu, Y.; Mao, Y. Q.; Kan, B.; Lei, S.; Wang, G. S.; Jiang, Y.; Wang, Q. R.; Luo, F.; Zou, L. Q.; Liu, J. Y. J. Induction of apoptosis by norcantharidin in human colorectal carcinoma cell lines: involvement of the CD95 receptor/ligand. Cancer Res. Clin. Oncol., 2002, 128, 223-230. (Pubitemid 34280381)
14. Chen, Y. J.; Kuo, C. D.; Tsai, Y. M.; Yu, C. C.; Wang, G. S.; Liao, H. F. Norcantharidin induces anoikis through Jun-N-terminal kinase activation in CT26 colorectal cancer cells. Anti-Cancer. Drugs, 2008, 19, 55-64.
15. Chen, Y. N.; Chen, J. C.; Yin, S. C.; Wang, G. S.; Tsauer, W.; Hsu, H. F.; Hsu, S. L. Effector mechanisms of norcantharidin-induced mitotic arrest and apoptosis in human hepatoma cells. Int. J. Cancer, 2002, 100, 158-165. (Pubitemid 34666189)
16. Williams, L. A.; Moller, W.; Merisor, E.; Kraus, W.; Rosner, H. In vitro antiproliferation/ cytotoxic activity of cantharidin (Spanish fly) and related derivatives. West. Ind. Med. J., 2003, 52, 10-13. (Pubitemid 36546631)
17. Huh, J. E.; Kang, K. S.; Chae, C.; Kim, H. M.; Ahn, K. S.; Kim, S. H. Roles of p38 and JNK mitogen-Activated protein kinase pathways during cantharidin-induced apoptosis in U937 cells. Biochem Pharmacol., 2004, 67, 1811-1818. (Pubitemid 38591370)
18. Wu, J. Z.; Situ, Z. Q.; Chen, J. Y.; Liu, B.; Wang, W. Chemosensitivity of salivary gland and oral cancer cell lines. Chin. Med. J., 1992, 105, 1026-1028. (Pubitemid 23034278)
19. Kok, S. H.; Chui, C. H.; Lam, W. S.; Chen, J.; Tang, J. C.; Lau, F. Y.; Cheng, G. Y.; Wong, R. S.; Chan, A. S. Apoptotic activity of a novel synthetic cantharidin analog on he-patoma cell lines. Int. J. Mol. Med., 2006, 17, 945-949.
20. Kok, S. H.; Chui, C. H.; Lam, W. S.; Chen, J.; Tang, J. C.; Lau, F. Y.; Cheng, G. Y.; Wong, R. S.; Chan, A. S. Apoptogenic activity of a synthetic cantharimide in leukaemia: implication on its structural activity relationship. Int. J. Mol. Med., 2006, 18, 1217-1221.
21. Li, W.; Xie, L.; Chen, Z.; Zhu, Y.; Sun, Y.; Miao, Y.; Xu, Z.; Han, X. Cantharidin, a potent and selective PP2A inhibitor, induces an oxidative stressindependent growth inhibition of pancreatic cancer cells through G2/M cellcycle arrest and apoptosis. Cancer Sci., 2010, 101, 1226-1233.
22. Janssens, V.; Goris, J. Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signaling. Biochem. J., 2001, 353, 417-439. (Pubitemid 32158309)
23. McCluskey, A.; Alistair T. R. S.; Sakoff, J. A. Serine-threonine protein phosphatase inhibitors:development of potential therapeutic strategies. J. Med. Chem., 2002, 45, 1151-1175. (Pubitemid 34263552)
24. Bonness, K.; Aragon, I. V.; Rutland, B.; Ofori-Acquah, S.; Dean, N. M.; Honkanen, R. E. Cantharidin-induced mitotic arrest is associated with the formation of aberrant mitotic spindles and lagging chromosomes resulting, in part, from the suppression of PP2A. Mol. Cancer. Ther., 2006, 5, 2727-2736. (Pubitemid 44848999)
25. Zeng, W. N.; Lu, Y. Advance on the synthesis and activities of cantharidin and its derivatives. Chin. J. Org. Chem., 2006, 26, 579-591. (Pubitemid 44065484)
26. Efferth, T.; Rauh, R.; Kahl, S.; Tomicic, M.; Bochzelt, H.; Tome, M. E.; Briehl, M. M.; Bauer, R.; Kaina, B. Molecular modes of action of cantharidin in tumor cells. Biochem. Pharmacol., 2005, 69, 811-818. (Pubitemid 40248623)
27. Murakami, S. Hepatitis B virus X protein: a multifunctional viral regulator. J. Gastroenterol., 2001, 36, 651-660. (Pubitemid 33040937)
28. Li, D.; Xie, K.; Wolff, R.; Abbruzzese, J. L. Pancreatic cancer. Lancet, 2004, 363, 1049-1057. (Pubitemid 38410779)
29. Guo, X.; Cui, Z. Current diagnosis and treatment of pancreatic cancer in China. Pancreas, 2005, 31, 13-22. (Pubitemid 40911497)
30. Zong, Y.; Li, W.; Chen, Z.; Zhu, Y.; Xu, Z. K.; Miao, Y. Cantharidin inhibits the growth and invasion ability of pancreatic cancer cells and the mechanism. Chin. J. Exp. Surg., 2011, 28, 177-179.
31. Zhang, W.; Liu, H. T. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res., 2002, 12, 9-18. (Pubitemid 135708299)
32. Schweyer, S.; Bachem, A.; Bremmer, F.; Steinfelder, H. J.; Soruri, A.; Wagner, W.; Pottek, T.; Thelen, P.; Hopker, W. W.; Radzun, H. J.; Fayyzai, A. Expression and function of protein phosphatase PP2A in malignant testicular germ cell tumours. J. Pathol., 2007, 213, 72-81. (Pubitemid 47354568)
33. Farrell, J. J.; van, Rijnsoever, M.; Elsaleh, H. Early detection markers in Pancreas Cancer. Cancer. Biomark., 2005, 1, 157-175.
34. Huan, S. K.H.; Lee, H. H.; Liu, D. Z.; Wu, C. C.; Wang, C. C. Cantharidininduced cytotoxicity and cyclooxygenase 2 expression in human bladder carcinoma cell line. Toxicol., 2006, 223, 136-143.
35. Wang, C.-C.; Wu, C.-H.; Hsieh, K.-J.; Yen, K.-Y.; Yang, L.-L. Cytotoxic effects of cantharidin on the growth of normal and carcinoma cells. Toxicol., 2000, 147, 77-87. (Pubitemid 30386908)
36. Sakoff, J. A.; Ackland, S. P.; Baldwin, M. L.; Keane, M. A.; McCluskey, A. Anticancer activity and protein phosphatase 1 and 2A inhibition of a new generation of cantharidin analogs. Invest. New Drugs, 2002, 20, 1-11. (Pubitemid 34251646)
37. Sakoff, J. A.; Howitt, I. J.; Ackland, S. P.; McCluskey, A. Serine/threonine protein phosphatase inhibition enhances the effect of thymidylate synthase inhibition. Cancer Chemother. Pharmacol., 2004, 53, 225-232. (Pubitemid 38293720)
38. Liu, X. H.; Blazsek, I.; Comisso, M.; Legras, S.; Marion, S.; Quittet, P.; Anjo, A.; Wang, G. S.; Misset, J. L. Effects of norcantharidin, a protein phosphatase type-2A inhibitor, on the growth of normal and malignant haemopoietic cells. Eur. J. Cancer, 1995, 31A, 953-963.
39. Yi, S. N.; Wass, J.; Vincent, P.; Iland, H. Inhibitory effect of norcantharidin on K562 human myeloid leukemia cells in vitro. Leuk. Res., 1991, 15, 883-886.
40. Efferth, T.; Davey, M.; Olbrich, A.; Rucker, G.; Gebhart, E.; Davey, R. Activity of drugs from traditional Chinese medicine toward sensitive and MDR1-or MRP1-overexpressing multidrug-resistant human CCRF-CEM leukemia cells. Blood Cell Mol. Dis., 2002, 28, 160-168. (Pubitemid 34743750)
41. Christmann, M.; Tomicic, M. T.; Roos, W. P.; Kaina, B. Mechanisms of human DNA repair: an update. Toxicol., 2003, 193, 3-34. (Pubitemid 37340141)
42. Sodeoda, M.; Baba, Y.; Kobayashi, S.; Hirukawa, N. Structure-Activity relationship of cantharidin derivatives to protein phosphatases 1, 2A1, and 2B. Bioorg. Med. Chem. Lett., 1997, 7, 1833-1836. (Pubitemid 27317798)
43. Isobe, M.; Ichikawa, Y.; Goto, T. Synthetic studies toward marine toxic polyethers. V. The total synthesis of okadaic acid. Tetrahedron Lett., 1986, 27, 963-966. (Pubitemid 16163696)
44. Yi, S. N. Inhibitory effect of norcantharidin on K562 human myeloid leukemia cells in vitro. Leuk. Res., 1991, 15, 883-886.
45. McCluskey, A.; Keane, M.A.; Mudgee, L. M.; Sim, A. T. R.; Sakoff, J.; Quinn, R. J. Anhydride modified cantharidin analogs. Is ring opening important in the inhibition of protein phosphatase 2A? Eur. J. Med. Chem., 2000, 35, 957-964.
46. Baba, Y.; Hirukawa, N.; Sodeoka, M. Optically active cantharidin analogs possessing selective inhibitory activity on Ser/Thr protein phosphatase 2B (calcineurin): implications for the binding mode. Bioorg. Med. Chem., 2005, 13, 5164-5170. (Pubitemid 41039976)
47. Massicot, F.; Dutertre-Catella, H.; Pham-Huy, C.; Liu, X. H.; Duc, H. T.; Warnet, J. M. In vitro assessment of renal toxicity and inflammatory events of two protein phosphatase inhibitors cantharidin and nor-cantharidin. Basic Clin. Pharmacol. Toxicol., 2005, 96, 26-32. (Pubitemid 40260843)
48. Deng, L. P.; Liu, F. M.; Wang, H. Y. 1,3-Dipolar cycloaddition reaction: synthesis of novel 5,6-dehydronorcantharidin derivatives of substituted aromatic amines with potential antitumor activities. J. Heterocycl. Chem., 2005, 42, 13-l8.
49. Purevsurev, G.; Koblicova, Z.; Trojanek, J. Cantharidinimide, a novel substance from mylabris mongolica dokht. Cesko-Slovenska. Pharm., 1987, 36, 32-34. (Pubitemid 17038791)
50. Tomita, K.; Sugai, S.; Kobayashi, T.; Murakami, T. Studies on isoxazoles. VIII. Versatile syntheses and chemical properties of 3-chloroisoxazolium chlorides. Chem. Pharm. Bull., 1979, 27, 2398-2404.
51. Padmavathi V.; Venugopal, R.K.; Padmaja, A.; Venugopalan, P. Unusual reaction of chloramine-T with araldoximes. J. Org. Chem., 2003, 68, 1567-1570. (Pubitemid 36232525)
52. Lee, J. Y.; Chung, Y. J.; Bae, Y. S.; Ryu, S. H.; Kim, B. H. Synthesis of hexapeptide and tetrapeptide analogs of the immunomodulating peptides. J. Chem. Soc. Perkin. Trans., 1998, 2, 359-366.
53. Berson, J. A.; Reynolds, R. D.; Jones, W. M. The stereochemistry and mechanism of the diels-Alder reaction. An "internal mechanism for the interconversion of endo-exo isomers. J. Am. Chem. Soc., 1956, 78, 6094-6097.
54. McCluskey, A.; Ackland, S. P.; Bowyer, M. C.; Baldwin, M. L.; Garner, J.; Walkom, C. C.; Sakoff, J. A. Cantharidin analogs: synthesis and evaluation of growth inhibition in a panel of selected tumour cell lines. Bioorg. Chem., 2003, 31, 68-79. (Pubitemid 36411927)
55. Chang, C.; Wu, J.; Zhang, J. M.; Zhu, Y. Q. Norcantharidin (NCTD) induces mitochondria mediated apoptosis in human HepG2 cells. Afr. J. Biotechnol., 2011, 10, 5370-5376.
56. Fan, Y. Z.; Zhao, Z. M.; Fu, J. Y.; Chen, C. Q.; Sun, W. Norcantharidin inhibits growth of human gallbladder carcinoma xenografted tumors in nude mice by inducing apoptosis and blocking the cell cycle in vivo. Hepatobiliary Pancreat. Dis. Int., 2010, 9, 414-422.
57. An, W. W.; Wang, M. W.; Tashiro, S. I.; Onodera, S.; Ikejima, T. Mitogenactivated protein kinase-dependent apoptosis in norcantharidin-treated A375-S2 cells is proceeded by the activation of protein kinase C. Chin. Med. J., 2005, 118, 198-203. (Pubitemid 40268171)
58. Yang, P. Y.; Chen, M. F.; Tsai, C. H.; Hu, D. N.; Chang, F. R.; Wu, Y. C. Involvement of caspase and MAPK activities in norcantharidin-induced colorectal cancer cell apoptosis. Toxicol. In Vitro., 2010, 24, 766-775.
59. Yang, H.; Guo, W.; Xu, B.; Li, M.; Cui, J. Anticancer activity and mechanisms of norcantharidin-Nd3II on hepatoma. Anticancer Drugs, 2007, 18, 1133-1137. (Pubitemid 47485648)
60. Li, G. Q.; Zhang, S. J.; Lü, J. F.; Wu, Y.; Li, J.; Zhang, G.; Yu, J. T. Molecular mechanism of norcantharidin inducing apoptosis in liver cancer cells. Zhonghua Yixue Zazhi, 2010, 90, 2145-2148.
61. Fan, Y. Z.; Fu, J. Y.; Zhao, Z. M.; Chen, C. Q. Inhibitory effect of norcantharidin on the growth of human gallbladder carcinoma GBC-SD cells in vitro. Hepatobiliary Pancreatic Disease Int., 2007, 6, 72-80.
62. Peng, C.; Liu, X.; Liu, E.; Xu, K.; Niu, W.; Chen, R.; Wang, J.; Zhang, Z.; Lin, P.; Wang, J.; Agrez, M.; Niu, J. Norcantharidin induces HT-29 colon cancer cell apoptosis through the v6-extracellular signal-related kinase signaling pathway. Cancer Sci., 2009, 100, 2302-2308.
63. Li, X. Q.; Shao, S. H.; Fu, G. L.; Han, X. H.; Gao, H. Study on norcantharidin-induced apoptosis in SMMC-7721 cells through mitochondrial pathways. Chin. J. Integr. Med., 2010, 16, 448-452.
64. Yang, E. B.; Tang, W. Y.; Zhang, K. Norcantharidin inhibits growth of human HepG2 cell-transplanted tumor in nude mice and prolongs host survival. Cancer Lett., 1997, 117, 93-98. (Pubitemid 27322920)
65. Sun, Z. X.; Ma, Q. W.; Zhao, T. D.; Wei, Y. L.; Wang, G. S.; Li, J. S. Apoptosis induced by norcantharidin in human tumor cells. World J. Gastroenterol., 2000, 6, 263-265. (Pubitemid 30223609)
66. Hong, C. Y.; Huang, S. C.; Lin, S. K.; Lee, J. J.; Chueh, L. L.; Lee, C. H.;Lin, J. H.; Hsiao, M. Norcantharidin-induced post-G2/M apoptosis is dependent on wild-type p53gene. Biochem. Biophys. Res. Commun., 2000, 276, 278-285.
67. Kok, S. H.; Cheng, S. J.; Hong, C. Y.; Lee, J. J.; Lin, S. K.; Kuo, Y. S.; Chiang, C. P.; Kuo, M. Y. P. Norcantharidin-induced apoptosis in oral cancer cells is associated with an increase of proapoptotic to antiapoptotic protein ratio. Cancer Lett., 2005, 217, 43-52.
68. Nagata, S. Apoptotic DNA fragmentation. Exp. Cell. Res., 2000, 10, 12-18. (Pubitemid 30211161)
69. Villa, P.; Kaufmann, S. H.; Eamshaw, W. C. Caspase and cas-pase inhibitors. Trends Biochem. Sci., 1997, 22, 388-393.
70. Stennicke, H. R.; Salvesen, S. Properties of the caspases. Biochim. Biophys. Acta., 1998, 1387, 17-31. (Pubitemid 28529204)
71. Salvesen, G. S.; Dixit, V. M. Caspases: intracellular signaling by proteolysis. Cell., 1997, 91, 443-446. (Pubitemid 27508233)
72. Takahashi, A.; Eamshaw, W. C. ICE-related proteases in apoptosis. Curr. Opin. Genet. Dev., 1996, 6, 50-55. (Pubitemid 26059051)
73. Enari, M.; Sakahira, H.; Yokoyama, H.; Okawa, K.; Iwamatsu, A.; Natata, S. A caspase-Activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature, 1998, 391, 43-50. (Pubitemid 28079208)
74. Chang, C.; Zhu, Y. Q.; Tang, X. Y.; Tao, W. H. The anti-proliferative effects of norcantharidin on human HepG2 cells in cell culture. Mol. Biol. Rep., 2011, 38, 163-169.
75. O'Neill, C. F.; Koberle, B.; Masters, J. R. W.; Kelland, L. R. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin. Br. J. Cancer, 1999, 81, 1294-1303.
76. Bednarski, P. Curr. Opin. Oncol. Endocr. Metab. Invest. Drugs, 1999, 1(4), 448-458.
77. Kelland, L. R.; Murrer, B. A.; Abel, G.; Giandomenico, C. M.; Mistry, P.; Harrap, K. R. Ammine/amine platinum (IV) dicarboxylates: a novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatinresistant human ovarian carcinoma cell lines. Cancer Res., 1992, 52, 822-888.
78. Shamsuddin, S.; Santillan, C. C.; Stark, J. L.; Whitmire, K. H.; Siddik, Z. H.; Khokhar, A. R. Synthesis, characterization, and antitumor activity of new platinum(IV) trans-carboxylate complexes: crystal structure of [Pt(cis-1,4-DACH)trans-(acetate)2Cl2]. J. Inorg. Biochem., 1998, 71, 29-35. (Pubitemid 28460818)
79. Lee, Y. A.; Lee, S. S.; Kim, K. M.; Lee, C. O.; Sohn, Y. S. Synthesis and oral antitumor activity of tetrakis(carboxylato)platinum(IV) complexes. J. Med. Chem., 2000, 43, 1409-1414.
80. Kizu, R.; Nakanishi, T.; Yamamoto, S.; Hayakawa, K.; Matsuzawa, A.; Eriguchi, M.; Takeda, Y.; Akiyama, N.; Kidani, Y. Significance of water solubility in the gastrointestinal absorption of trans-bis(n-valerato) (1R,2Rcyclohexanediamine) (oxalato)platinum(IV), an orally active antitumor platinum complex, and its analogs. Anticancer Drugs, 1998, 9, 167-174. (Pubitemid 28080638)
81. Kizu, R.; Nakanishi, T.; Hayakawa, K.; Matsuzawa, A.; Eriguchi, M.; Takeda, Y.; Akiyama, N.; Tashiro, T.; Kidani, Y. A new orally active antitumor 1R,2R-cyclohexanediamine-platinum(IV)complex: trans-(nvalerato) chloro(1R,2 R-cyclohexanediamine) (oxalato)platinum(IV). Cancer Chemother. Pharmacol., 1999, 43, 97-105. (Pubitemid 29045026)
82. Khokhar, A. R.; Al-Baker, S.; Shamsuddin, S.; Siddik, Z. H. Chemical and biological studies on a series of novel (trans-(1R,2R)-,trans-(1S,2S)-,and cis-1,2-diaminocyclohexane)platinum(IV) carboxylate complexes. J. Med. Chem., 1997, 40, 112-116. (Pubitemid 27027272)
83. Lee, E. J.; Jun, M. J.; Sohn, Y. S. Synthesis and properties of novel platinum( IV) complexes involving asymmetric chiral diamines as carrier ligands. Bull. Korean Chem. Soc., 1999, 20, 1295-1298.
84. Wong, E.; Giandomenico, C. M. Current status of platinum-based antitumor drugs. Chem. Rev., 1999, 99, 2451-2466.
85. Bierbach, U.; Sabat, M.; Farrell, N. Inversion of the cis geometry requirement for cytotoxicity in structurally novel platinum(II) complexes containing the bidentate N,O-donor pyridin-2-yl-Acetate. Inorg. Chem., 2000, 39, 1882-1890.
86. Coluccia, M.; Nassi, A.; Loseto, F.; Boccarelli, A.; Mariggio, M. A.; Giordano, D.; Intini, F. P.; Caputo, P.; Natile, G. A trans-platinum complex showing higher antitumor activity than the cis congeners. J. Med. Chem., 1993, 36, 510-512. (Pubitemid 23065311)
87. Bierbach, U.; Qu, Y.; Hambley, T. W.; Peroutka, J.; Nguyen, H. L.; Doedee, M.; Farrell, N. Synthesis, structure, biological activity, and DNA binding of platinum(II) complexes of the type trans-[PtCl2(NH3)L] (L= planar nitrogen base). Effect of L and cis/trans isomerism on sequence specificity and unwinding properties observed in globally platinated DNA. Inorg. Chem., 1999, 38, 3535-3542.
88. Montero, E. I.; Diaz, S.; Gonzalez-Vadillo, A. M.; Perez, J. M.; Alonso, C.; Navarro-Ranninger, C. Preparation and characterization of novel trans- [PtCl2(amine)(isopropylamine)] compounds:cytotoxic activity and apoptosis induction in ras-transformed cells. J. Med. Chem. 1999 42 4264-4268. (Pubitemid 29483044)
89. O'Neill, C. F.; Hunakova, L.; Kelland, L. R. Cellular pharmacology of cis and trans pairs of platinum complexes in cisplatin-sensitive and -resistant human ovarian carcinoma cells. Chem. Biol. Interact., 1999, 123, 11-29. (Pubitemid 29505247)
90. Giaccone, G. Clinical perspectives on platinum resistance. Drugs, 2000, 59, 9-17. (Pubitemid 30344987)
91. Tashiro, T.; Kawada, Y.; Sakurai, Y.; Kidani, Y. Antitumor activity of a new platinum complex, oxalato (trans-l-1,2-diaminocyclohexane)platinum (II): new experimental data. Biomed. Pharmacother., 1989, 43, 251-260. (Pubitemid 19153976)
92. Rixe, O.; Ortuzar, W.; Alvarez, M.; Parker, R.; Paull, K.; Fojo, R. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drugresistant cell lines and in the cell lines of the National Cancer Institute's anticancer drug screen panel. Biochem. Pharmacol., 1996, 52, 1855-1865. (Pubitemid 26419675)
93. Ho, Y. P.; To, K. K. W.; Au-Yeung, S. C. F.; Wang, X. N.; Lin, G.; Han, X. W. Potential new antitumor agents from an innovative combination of demethylcantharidin, a modified traditional Chinese medicine, with a platinum moiety. J. Med. Chem., 2001, 44, 2065-2068. (Pubitemid 32861766)
94. To, K. K. W.; Ho, Y. P.; Au-Yeung, S. C. F. Synergistic interaction between platinum-based antitumor agents and demethylcantharidin. Cancer Lett., 2005, 223, 227-237. (Pubitemid 40719621)
95. Yu, C. W.; Li, K. K. W.; Pang, S. K.; Au-Yeung, S. C. F.; Ho, Y. P. Anticancer activity of a series of platinum complexes integrating demethylcantharidin with isomers of 1,2-diaminocyclohexane. Bioorg. Med. Chem. Lett., 2006, 16, 1686-1691. (Pubitemid 43197546)
96. Au-Yeung, S. C. F.; Pang, P. S. K.; Ho, Y. P. Innovative platinum derived anticancer agents-risk or opportunity? Nat. Rev. Drug Discov., 2006, 5, 5-9.
97. Pang, S. K.; Yu, C. W.; Au-Yeung, S. C. F.; Ho, Y. P. DNA damage induced by novel demethylcantharidin-integrated platinum anticancer complexes. Biochem. Biophys. Res. Commun., 2007, 363, 235-240. (Pubitemid 47432918)
98. Bajsa, J.; McCluskey, A.; Gordon, C. P.; Stewart, S. G.; Hill, T. A.; Sahu, R.; Duke, S. O.; Tekwani, B. L. The antiplasmodial activity of norcantharidin analogs. Bioorg. Med. Chem. Lett., 2010, 20, 6688-6695.